Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Safety & Availability (Biologics)

Safety & Availability (Biologics)

                        Biologic Product Security
          Blood Safety & Availability
          CBER-Regulated Products: Shortages and Discontinuations
          Pandemics & Emerging Diseases
          Tissue Safety & Availability
          Vaccine Safety & Availability


                        HIV Home Test Kits
          Recalls (Biologics)
          Report a Problem to the Center for Biologics Evaluation & Research Home
          Vaccines, Blood & Biologics
          Safety & Availability (Biologics)
          Testing Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P): Specific RequirementsSafety & Availability (Biologics) Testing Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P): Specific Requirements
  
  	
    Share
    Post
    Linkedin

    Email
    PrintYou must test **all donors of HCT/Ps**, unless subject to an exception in § 1271.90, for relevant communicable disease agents or diseases, as required in § 1271.85 and further described in applicable FDA guidance documents. You must use an FDA-licensed, approved, or cleared donor screening test when such a test is available, as described in § 1271.80(c). Current FDA-licensed, cleared or approved donor screening tests for use in testing HCT/P donors are listed at the Testing HCT/P Donors for Relevant Communicable Disease Agents and Diseases page. Additional tests acceptable for use to screen living donors may also be listed at the Complete List of Donor Screening Assays for Infectious Agents and HIV Diagnostic Assays page. Our recommendations on specific tests may change in the future due to technological advances or evolving scientific knowledge. The tests listed adequately and appropriately reduce the risk of transmission of relevant communicable disease.

You must test **all** donors of HCT/Ps for the following diseases:

**HIV, type 1** using an FDA-licensed donor screening test either for anti-HIV-1 or combination test for anti-HIV-1 and anti-HIV-2; and FDA-licensed donor screening NAT assay for HIV-1, or combination NAT that includes HIV-1 (establishments not utilizing an FDA-licensed donor screening test that tests for group O antibodies must screen donors for risk associated with HIV group O infection);
	**HIV, type 2**using an FDA-licensed donor screening test either for anti-HIV-2 or combination test for anti-HIV-1 and anti-HIV-2;
	**HBV** using an FDA-licensed donor screening test for Hepatitis B surface antigen (HBsAg); FDA-licensed donor screening test for total antibody to Hepatitis B core antigen (anti-HBc)(IgG and IgM); and FDA-licensed donor screening NAT assay for HBV, or combination NAT that includes HBV;
	**HCV** using an FDA-licensed donor screening test for anti-HCV; and FDA-licensed donor screening NAT assay for HCV, or combination NAT that includes HCV; and
	***Treponema pallidum*** using an FDA-cleared donor screening test for syphilis.For **living** donors of HCT/Ps, you must **also** test for the following diseases:

**WNV** using an FDA-licensed donor screening NAT assay for WNV.For donors of **viable, leukocyte-rich HCT/Ps**, you must **also** test for the following diseases:

**Human T-lymphotropic virus, types I and II** using an FDA-licensed donor screening test for anti-HTLV I/II; and
	**Cytomegalovirus** using an FDA-cleared donor screening test for anti-CMV (total IgG and IgM).For donors of **reproductive HCT/Ps** (unless excepted in § 1271.90), you must **also** test for the following diseases:

***Chlamydia trachomatis*** using an FDA-licensed, approved, or cleared test labeled for the detection of those organisms in an asymptomatic, low-prevalence population; and
	***Neisseria gonorrhea*** using an FDA-licensed, approved, or cleared test labeled for the detection of those organisms in an asymptomatic, low-prevalence population.Additional information about donor testing can be found in the following guidance documents:

Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products, dated 8/2007;

Guidance for Industry: Use of Donor Screening Tests to Test Donors of Human Cells, Tissues and Cellular and
Tissue-Based Products for Infection with Treponema pallidum (Syphilis), dated 9/2015;

Guidance for Industry: Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from
Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products, dated 8/2016; and

Guidance for Industry: Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Product s (HCT/Ps), dated 9/2016.

                                                                                  Content current as of:
      05/03/2019
              
              
Regulated Product(s)
		 Biologics
			  			     			  						              
			
			 
			  TissueSafety & Availability (Biologics)

          
                        Biologic Product Security
          Blood Safety & Availability
          CBER-Regulated Products: Shortages and Discontinuations
          Pandemics & Emerging Diseases
          Tissue Safety & Availability
          Vaccine Safety & Availability


                        HIV Home Test Kits
          Recalls (Biologics)
          Report a Problem to the Center for Biologics Evaluation & Research
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop